Clinical Trial Detail

NCT ID NCT04160052
Title Venetoclax and Azacitidine for the Treatment of High-Risk Recurrent or Refractory Myelodysplastic Syndrome
Recruitment Recruiting
Gender both
Phase Phase Ib/II
Variant Requirements No
Sponsors M.D. Anderson Cancer Center
Indications

myelodysplastic syndrome

chronic myelomonocytic leukemia

Therapies

Azacitidine + Venetoclax

Age Groups: adult senior

No variant requirements are available.